1、国家自然科学基金面上项目，81573636，人参皂苷Rg1通过调控星形胶质细胞网络缝隙连接细胞间通讯功能发挥抗抑郁作用的机理研究，2016/01-2019/12，77.4万元，项目负责人。

2、国家自然科学基金青年科学基金项目，81202507，基于脑内PDE4D4/5的新型抗抑郁药物潜在靶标的研究，2013/01-2015/12，23万元，项目负责人。

3、北京市自然科学基金面上项目，7142115，PDE4D4/5作为治疗阿尔茨海默病认知障碍潜在新靶标的研究，2014/01-2016/12，18万元，项目负责人。

4、北京市自然科学基金面上项目，7182114，通过调控AMPAR/mTORC1信号通路研发快速起效抗抑郁药的应用基础研究，2018/01-2020/12，20万元，项目负责人。

5、国家“重大新药创制”科技重大专项，2018ZX09711001-002-007，IMM-H004柠檬酸盐的临床前研究，2018/1-2020/12，379.41万，任务负责人。

6、国家“重大新药创制”科技重大专项，2018ZX09711001-009-013，天然药物有效成分群间功效关联性评价关键技术研究1-7，2018/1-2020/12，48.26万，任务负责人。

7、中国医学科学院中央级公益性科研院所基本科研业务费青年医学人才奖励项目，水通道4通过miR221调节缝隙连接蛋白Cx43的抑郁症发病机制研究，2018/10-2019/09，50万元，项目负责人。

8、中国医学科学院基本科研业务费创新人才培养专项，2014RC03，基于缝隙连接蛋白Cx43的人参皂苷Rg1抗抑郁作用机制研究，2014/01-2016/12，42万元，项目负责人。

9、北京协和医学院协和青年基金，3332016058，基于缝隙连接功能和半通道功能研究Rg1的抗抑郁作用机制，2016/04-2018/03，15万元，项目负责人。

10、首都医科大学神经变性病教育部重点实验室开放课题，2016SJBX03，基于DJ-1/GSK-3靶点研究知母皂苷A-III保护线粒体功能抗帕金森病的作用机制，2016/01-2017/12，5万元，项目负责人。

11、烟台大学分子药理和药物评价教育部重点实验室开放课题，P201807，采用高内涵筛选系统构建和评价抗抑郁化合物体外筛选模型，2019/01-2020/12，4万元，项目负责人。

12、中国医学科学院医学与健康科技创新工程重大协同创新项目，2016-I2M-1-004，神经科学与重大神经退行性疾病防治研究，2016/09-2020/12，50万元/年，岗位负责人。

13、国家自然科学基金云南联合基金，U1402221，基于云天麻的新型联苄类化合物抗帕金森病作用机制及成药性研究，2015/01-2018/12，223万元，参加。

14、国家自然科学基金重点项目，81730096，以CKLF1为新型药物靶标的发现及其抗缺血性损伤的系统性药理学研究，2018/01-2022/12，290万元，参加。

15、国家自然科学基金面上项目，81773924，抗抑郁药物新靶标Cx43的功能解析及人参皂苷Rg1对其干预的机制研究，2018/01-2021/12，57万元，参加。

16、国家自然科学基金面上项目，81473376，从DJ-1介导JNK信号通路角度探讨知母宁对帕金森病线粒体功能的作用机制，2015/01-2018/12，68万元，参加。

17、国家自然科学基金面上项目，81573640，人参皂苷Rg1通过α-突触核蛋白介导的炎症通路干预帕金森病的机制研究，2016/01-2019/12，74万元，参加。

18、国家自然科学基金面上项目，81473570，基于治胆从肝理论干预胆石症的作用机制研究，2015/01-2018/12，72万元，参加。

19、国家自然科学基金面上项目，81072624，基于PDE4D的抗抑郁药潜在新靶标及其调节机制的研究，2011/01-2014/12，36万元，参加。

20、国家自然科学基金面上项目，81173036，TSPO与创伤后应激障碍（PTSD）的关系及作为其新型潜在治疗靶标的研究，2012/01-2015/12，60万元，参加。

21、国家自然科学基金青年科学基金项目，81102423，新型5-HT1A受体激动和5-HT重摄取抑制双靶标抗抑郁剂快速起效的5-HT1A受体机制研究，2012/01-2014/12，22万元，参加。

22、国家自然科学基金青年科学基金项目，81001653，小补心汤总黄酮抑制海马一氧化氮释放抗创伤后应激障碍的神经生物学机制，2011/01-2013/12，20万元，参加。

发表文章

1.      Xia CY#, Wang ZZ#,Wang HQ, Ren SY, Lou YX, Jin C, Qu TG, Feng ST, Zhang Y, Chu SF, Chen NH*. Connexin 43: A novelginsenoside Rg1-sensitive target in a rat model of depression. Neuropharmacology,2020;170:108041.

2.      Lou YX#, Wang ZZ#, *,Xia CY, Mou Z, Ren Q, Liu DD, Zhang X, Chen NH*. The protective effect of ginsenoside Rg1 on depressionmay benefit from the gap junction function in hippocampal astrocytes. European Journal of Pharmacology, 2020;882:173309.

3.     Wang HQ, Yang SW, Gao Y, Liu YJ,Li X, Ai QD, Lin MY, Yang YT, Zeng Q, Zhang Y, Wang ZZ*, Chen NH*. Novelantidepressant mechanism of ginsenoside Rg1: Regulating biosynthesis anddegradation of connexin43. Journal ofEthnopharmacology，2021: 114212.

4.      Xia CY, Chu SF, Zhang S, Gao Y,Ren Q, Lou YX, Luo P, Tian MT, Wang ZQ, Du GH, Tomioka Y, Yamakuni T, Zhang Y, Wang ZZ*, Chen NH*.Ginsenoside Rg1 alleviates corticosterone-induced dysfunction of gap junctionsin astrocytes. Journal ofEthnopharmacology, 2017; 208: 207-213.

5.     Zhang YN, Zhang XL, Liu N, RenSY, Xia CY, Yang X, Lou YX, Wang HQ, Zhang NN, Yan X, Zhang Z, ZhangY, Wang ZZ*, ChenNH*. Comparative proteomic characterization of ventral hippocampusin susceptible and resilient rats subjected to chronic unpredictable stress. Frontiers in Neuroscience, 2021; doi:10.3389/fnins.2021.675430.

6.      Wang HQ, Wang ZZ*, ChenNH*. The receptor hypothesisand the pathogenesis of depression: Genetic bases and biological correlates. Pharmacological Research, 2021; 167: 105542.

7.     Wang ZZ, ZhangY, Liu YQ, Zhao N, Zhang YZ, Yuan L, An L, Li J, Wang XY, Qin JJ,Wilson SP, O’Donnell JM, Zhang HT, Li YF*. RNA interference-mediated phosphodiesterase-4D splice variants knockdown in theprefrontal cortex produces antidepressant-like and cognition-enhancing effects.British Journal of Pharmacology, 2013;168: 1001-1014.

8.     Wang ZZ,Yang WX, Zhang Y, Zhao N, Zhang YZ, Liu YQ, Xu Y, Wilson SP, O’Donnell JM,Zhang HT, Li YF*. Phosphodiesterase-4D Knock-down inthe Prefrontal Cortex Alleviates Chronic Unpredictable Stress-InducedDepressive-Like Behaviors and Memory Deficits in Mice. Scientific Reports, 2015; 5: 11332.

9.     YangPF#, Wang ZZ#, ZhangZ, Liu DD, Manolios EN, Chen C, Yan X, Zuo W, Chen NH*, The extended application of The Rat Brain in Stereotaxic Coordinatesin rats of various body weight. Journalof Neuroscience Methods, 2018; 307: 60-69.

10.   Wang ZZ, Zhang Y, Zhang HT, Li YF*. Phosphodiesterase(PDEs): An interface connecting cognitive deficits to neuropsychiatric andneurodegenerative diseases. Current Pharmaceutical Design, 2015;21: 303-316.

11.    Wang XL, Feng ST, Wang YT, Yuan YH, LiZP, Chen NH, Wang ZZ*,Zhang Y*. Mitophagy, aForm of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamicsof Parkinson's Disease. Cellular andMolecular Neurobiology, 2021; doi: 10.1007/s10571-021-01039-w.

12.   Wang ZZ,Li G, Chen XY, Zhao M, Yuan YH, WangXL, Chen NH*. Chemokine-likefactor 1, a novel cytokine, induces nerve cell migration through thenon-extracellular Ca2+-dependent tyrosine kinases pathway. Brain Research, 2010; 1308: 24-34.

13.   Wang ZZ, Zhang Y,Yuan YH, Chen NH*. Developmental expression of chemokine-likefactor 1, a novel member of chemokines family, in postnatal rat cerebral cortex.NeuroscienceLetters, 2012; 519: 51-55.

14.   Wang ZZ, Yuan YH, Zhang Y, Wang XF, Chu SF, Han N, Chen NH*.Chemokine-likefactor 1 promotes the migration of rat primary cortical neurons by theinduction of actin polymerization. Neuroreport, 2014; 25:1221-1226.

15.   Wang ZZ, Zhao WJ, Zhang XS, Tian XF, Wang YZ, Zhang F, YuanJC, Han GZ, Liu KX, Yao JH*. Protection of Veratrum nigrum L. var. ussuriense Nakaialkaloids against ischemia-reperfusion injury of the rat liver. World Journal of Gastroenterology, 2007;13: 564-571.

16.   ZhangY#, *, Wang ZZ#, Sun HM, Li P,Li YF, Chen NH. Systematic review of traditional chinese medicine fordepression in Parkinson's disease. AmericanJournal of Chinese Medicine, 2014; 42: 1035-1051.

17.   Xia CY, Wang ZZ, Zhang Z, Chen J, Wang YY, Lou YX, Gao Y, Luo P, RenQ, Du GH, Chen NH*. Corticosterone impairs gap junctions in theprefrontal cortical and hippocampal astrocytes via different mechanisms. Neuropharmacology, 2017; 131: 20-30.

18.   XiaCY, Wang ZZ, Tomioka Y, Chen NH*. A novel mechanismof depression: role for connexins. European Neuropsychopharmacology,2018; 28(4): 483-498.

19.   Jin C, Wang ZZ, Zhou H, Lou YX, Chen J, Zuo W, Tian MT, Wang ZQ, DuGH, Kawahata I, Yamakuni T, Zhang Y, Chen NH*, Zhang DS*.Ginsenoside Rg1-induced antidepressant effects involve the protection ofastrocyte gap junctions within the prefrontal cortex. Progress in neuro-psychopharmacology & biological psychiatry, 2017; 75: 183-191.

20.    Chen J, Wang ZZ, Zhang S, Chu SF, MouZ, Chen NH*. The effects of glucocorticoids on depressive andanxiety-like behaviors, mineralocorticoid receptor-dependent cell proliferationregulates anxiety-like behaviors. Behavioural Brain Research, 2019; 362: 288-298.

21.   ChenJ, Wang ZZ, Zuo W, Zhang S, Chu SF, Chen NH*. Effectsof chronic mild stress on behavioral and neurobiological parameters - Role ofglucocorticoid. Hormones and Behavior,2015; 78: 150-159.

22.   Chen J, Wang ZZ, Zhang S, Ai QD, Chu SF, Chen NH*.Possible target-related proteins of stress-resistant rats suggested bylabel-free protemic analysis. RSC Advances, 2017; 7: 40957-40964.

23.    Chen J, Wang ZZ, Zhang S, Zuo W, ChenNH*. Does mineralocorticoid receptor play a vital role in thedevelopment of depressive disorder? LifeSciences, 2016; 152: 76-81.

24.   Ren Q,Wang ZZ, Chu SF, Xia CY, Chen NH*. Gap junctionchannels as potential targets for the treatment of major depressive disorder.Psychopharmacology (Berl), 2018; 235(1):1-12.

25.   Liu N, Wang ZZ, Zhao M, Zhang Y, ChenNH*. Role of Non-coding RNA in thePathogenesis of Depression. Gene, 2020;735:144276.

26.   Ren SY, WangZZ, Zhang Y, Chen NH*. Potential Application of Endocannabinoid System Agents inNeuropsychiatric and Neurodegenerative Diseases-Focusing onFAAH/MAGL Inhibitors. ActaPharmacologica Sinica, 2020; 41(10):1263-1271.

27.   Zhang XL, Wang ZZ, Shao QH, Zhang Z, Li L, Guo ZY, Sun HM, Zhang Y*, Chen NH*. RNAi-mediated knockdownof DJ-1 leads to mitochondrial dysfunction via Akt/GSK-3ss and JNK signalingpathways in dopaminergic neuron-like cells. BrainRes Bull, 2019;146:228-236.

28.   Feng ST,Wang ZZ, Yuan YH, Sun HM, Chen NH, Zhang Y*. Mangiferin: A multipotent natural product preventingneurodegeneration in Alzheimer's and Parkinson's disease models. Pharmacological Research, 2019;146:104336.

29.    Feng ST, Wang ZZ, Yuan YH, Sun HM, Chen NH, Zhang Y*. Update on the association between alpha-synuclein and tauwith mitochondrial dysfunction: Implications for Parkinson's disease. European Journal of Neuroscience, 2021; 53(9):2946-2959.

30.   Feng ST,Wang ZZ, Yuan YH, Wang XL, Sun HM, Chen NH, Zhang Y*. Dynamin-related protein 1: Acritical protein in mitochondrial fission, mitophagy, and neuronal death ofParkinson’s disease. PharmacologicalResearch, 2020;151:104553.

31.   ZhangY, Wang ZZ, Sun HM*. Lack of association betweenp.Ser167Asn variant of Parkin and Parkinson's disease: A meta-analysis of 15studies involving 2,280 cases and 2,459 controls. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics,2012; 159B: 38-47.

32.    Zhang Y, Wang ZZ, Sun HM*.A meta-analysis of the relationship of the Parkin p.Val380Leu polymorphism toParkinson’s disease. American Journal ofMedical Genetics Part B: Neuropsychiatric Genetics, 2013; 162: 235-244.

33.   ZhangY, Wang ZZ, Sun HM*. Meta-analysis of the influence ofParkin p.Asp394Asn variant on the susceptibility of Parkinson's disease. Neuroscience Letters, 2012; 524: 60-64.

34.   LouYX, Li J, Wang ZZ, Xia CY, Chen NH*. Glucocorticoid receptor activation induces decrease of hippocampalastrocyte number in rats. Psychopharmacology(Berl), 2018; 235(9): 2529-2540.

35.    Yang X, Chu SF, Wang ZZ, Li FF, YuanYH, Chen NH*. Ginsenoside Rg1 exerts neuroprotective effects in3-nitropronpionic acid-induced  mousemodel of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum. Acta PharmacologicaSinica, 2020; doi: 10.1038/s41401-020-00558-4

36.    Wang XL, Feng ST, Wang ZZ, Chen NH,Zhang Y*. Role of mitophagy in mitochondrial quality control:Mechanisms and potential implications for neurodegenerative diseases. Pharmacological Research, 2021; 165: 105433.

37.    Wang XL, Feng ST, Wang ZZ, Yuan YH,Chen NH, Zhang Y*. Parkin, an E3 Ubiquitin Ligase, Plays anEssential Role in Mitochondrial Quality Control in Parkinson's Disease. Cellular and Molecular Neurobiology,2020; doi: 10.1007/s10571-020-00914-2

38.   Zhang Y*,Gong XG, Wang ZZ, Sun HM*, Guo ZY, Hu JH, Ma L, Li P,Chen NH. Overexpression of DJ-1/PARK7, the Parkinson's disease-related protein,improves mitochondrial function via Akt phosphorylation on threonine 308 indopaminergic neuron-like cells. EuropeanJournal of Neuroscience, 2016; 43(10): 1379-1388.

39.   Zhang Y#, *,Gong XG#,Wang ZZ, Sun HM*, Guo ZY, Gai C, Hu JH, Ma L,Li P Chen NH. Protective effectsof DJ-1 medicated Akt phosphorylation on mitochondrial function are promoted byDa-Bu-Yin-Wan in 1-methyl-4-phenylpyridinium-treated human neuroblastomaSH-SY5Y cells. Journal ofEthnopharmacology, 2016; 187: 83-93.

40.   Li G*, LiGY, Wang ZZ, Ji HJ, Wang DM,Hu JF, Yuan YH, Liu G, Chen NH*.Thechemokine-like factor 1 induces asthmatic pathological change by activatingnuclear factor-kappaB signaling pathway. InternationalImmunopharmacology, 2014; 20(1): 81-88.

41.   Yao JH, Li YH, Wang ZZ, Zhang XS, Wang YZ, YuanJC, Zhou Q, Liu KX, Tian XF*.Proteasomeinhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion.Clinical and Experimental Pharmacologyand Physiology, 2007; 34: 1102-1108.

42.   ZhangXL, Yuan YH, Shao QH, WangZZ, Zhu CG, Shi JG, Ma KL, Yan X, Chen NH*. DJ-1 regulatingPI3K-Nrf2 signaling plays a significant role in bibenzyl compound 20C-mediatedneuroprotection against rotenone-induced oxidative insult. Toxicology Letters, 2017;271: 74-83.

43.   XiaCY, Zhang S, Gao Y, Wang ZZ, Chen NH*. Selective modulation ofmicroglia polarization to M2 phenotype for stroke treatment.International Immunopharmacology,2015; 25: 377-382.

44.   XiaCY, Zhang S, Chu SF, Wang ZZ, Song XY, Zuo W, Gao Y, Yang PF,Chen NH*. Autophagic flux regulates microglial phenotype accordingto the time of oxygen-glucose deprivation/reperfusion. International Immunopharmacology, 2016; 39: 140-148.

45.   ZhouH, Xue W, Chu SF, WangZZ, Li CJ, Jiang YN, Luo LM, LuoP, Li G, Zhang DM and Chen NH*. Polygalasaponin XXXII, atriterpenoid saponin from Polygalae Radix, attenuates scopolamine-inducedcognitive impairments in mice. ActaPharmacologica Sinica, 2016; 37(8): 1045-1053.

46.   Tian XF, Zhang XS, Li YH, Wang ZZ, Zhang F, Wang LM, YaoJH*. Proteasomeinhibition attenuates lung injury induced by intestinal ischemia reperfusion inrats. Life Sciences, 2006; 79:2069-2076.

47.   Kong LL, Wang ZY, Han N, ZhuangXM, Wang ZZ, Li H*, Chen NH*. Neutralization ofchemokine-like factor 1, a novel C-C chemokine, protects against focal cerebralischemia by inhibiting neutrophil infiltration via MAPK pathways in rats. Journal of Neuroinflammation, 2014; 11:112.

48.   Zhang Z, Chu SF, Mou Z, Gao Y, Wang ZZ, Wei GN, Chen NH*. Ganglioside GQ1b inducesdopamine release through the activation of Pyk2. Molecular and Cellular Neuroscience, 2016; 71: 102-113.

49.   Tian XF, Yao JH, Li YH, Gao HF, Wang ZZ, Yang CM, Zheng SS*. Protective effect ofpyrrolidine dithiocarbamate on liver injury induced by intestinalischemia-reperfusion in rats. Hepatobiliary& Pancreatic Diseases International, 2006; 5: 90-95.

50.   Yao JH, Zhang XS, Zheng SS, LiYH, Wang LM, Wang ZZ,Chu L, Hu XW, Liu KX, Tian XF*.Prophylaxis with carnosol attenuates liver injury induced by intestinalischemia/reperfusion. World Journal ofGastroenterology, 2009; 15: 3240-3245.

51.   Dong YX, Chu SF, Wang SS, TianYJ, He WB, Du YS, Wang ZZ,Yan X, Zhang Z*, ChenNH*. Rg1 exertsprotective effect in CPZ-induced demyelination mouse model via inhibiting CXCL10-mediatedglial response. Acta PharmacologicaSinica, 2021; doi: 10.1038/s41401-021-00696-3.

52.   Tian XF, Yao JH*, Zhang XS, ZhengSS, Guo XH, Wang LM, Wang ZZ,Liu KX. Protective effect of carnosol on lung injuryinduced by intestinal ischemia/reperfusion. Surgery Today, 2010; 40: 858-865.

53.   Chu SF#, ZhangZ#, Zhou X, He WB, Yang B, Cui LY, He HY, Wang ZZ, Chen NH*. Low corticosterone levelsattenuate late life depression and enhance glutamatergic neurotransmission infemale rats. Acta Pharmacologica Sinica,2020; 42(6):848-860.

54.   Gao Y, Chu SF, Li JP, Zhang Z,Yan JQ, Wen ZL, Xia CY, Mou Z, WangZZ, He WB, Guo XF, Wei GN, Chen NH*.Protopanaxtriol protects against3-nitropropionic acid-induced oxidative stress in a rat model ofHuntington's disease. Acta Pharmacologica Sinica,2015; 36: 311-322.

55.   Zhang Y#,*, Gong XG#, Sun HM*, Guo ZY, Hu JH, Wang YY, FengWD, Li L, Li P, Wang ZZ, ChenNH. Da-Bu-Yin-Wan Improves the Ameliorative Effect of DJ-1 on MitochondrialDysfunction Through Augmenting the Akt Phosphorylation in a Cellular Model ofParkinson's Disease. Front Pharmacol 2018;9: 1206.

56.   Chu SF, Zhang Z, Zhou X, He WB,Chen C, Luo P, Liu DD, Ai QD, Gong HF, WangZZ, Sun HS, Feng ZP, Chen NH*.Ginsenoside Rg1 protects against ischemic/reperfusion-induced neuronal injurythrough miR-144/Nrf2/ARE pathway. Acta Pharmacol Sin, 2019;40(1):13-25.

57.   王真真, 陈乃宏*. 抑郁症与炎症. 神经药理学报, 2013; 3: 27-37.

58.    王真真,张有志, 宫泽辉, 李云峰*.抑郁症治疗的新靶点和新策略. 中国药理学与毒理学杂志, 2010; 24: 364-370.

59.   王真真, 苑玉和, 韩宁, 张毅, 陈乃宏*.CKLF1通过激活PLC-γ/FAK信号途径促进SH-SY5Y细胞迁移. 中国药理学通报, 2014; 30: 1209-1213.

60.   王真真, 张有志, 宫泽辉, 李云峰*. 抗精神分裂症药物的研究进展. 军事医学, 2013; 37: 628-631+640.

61.   王真真, 胡金凤, 李刚, 陈乃宏*. 趋化因子及其受体在神经系统发育中的作用. 生命科学, 2007; 19: 536-542.

62.   杨卫星#,王真真#,龚晓健*, 李云峰*. 磷酸二酯酶4（PDE4）：抑郁症治疗新靶点. 国际药学研究杂志，2014; 41: 291-295.

63.   任 倩#, 夏聪媛#, 王真真*,陈乃宏*.人参皂苷Rg1 对皮质酮介导原代星形胶质细胞损伤的保护作用. 药学学报, 2017;52 (9): 1410−1415.

64.   温智林, 王真真, 贺文彬*, 陈乃宏*. 开心散含药血清对皮质酮所致CTXTNA2细胞损伤的保护作用.神经药理学报,2014; 4: 1-5.

65.    刘诺, 王真真, 陈乃宏*. 缝隙连接蛋白Connexin 43参与神经精神疾病发病机制的研究进展. 中国药理学通报, 2019; 35(2): 156-158.

66.   任思宇, 王真真, 陈乃宏*. 人参皂苷抗抑郁作用研究进展. 药学学报, 2019, 54(12): 2204-2208.

67.   王惠芹, 王真真,陈乃宏*. 抑郁症发病与受体基因异常研究进展. 药学学报, 2020, 55(3): 384-391.

68.    任倩, 王真真, 陈乃宏*. MicroRNA调控神经可塑性在抑郁症中作用研究进展. 神经药理学报, 2017; 7(3): 12-20.

69.   张小玲, 王真真, 温路, 邵千航, 陈乃宏*. 细胞因子与抑郁症关系的研究进展. 神经药理学报, 2016; 6: 31-36.

70.    刘诺, 王真真, 陈乃宏*. 肠道菌群在阿尔茨海默氏症发病中的作用. 神经药理学报 2017;7(5):28-33.

71.    温智林, 王真真, 贺文彬*, 陈乃宏*. 开心散及其有效成分抗抑郁作用的研究进展. 中药新药与临床药理, 2015; 26: 420-423.

72.   周恒, 王真真, 陈乃宏. 补益药抗衰老作用机制研究进展. 湖南中医药大学学报, 2015; 35(12): 11-13.

73.   陈姣, 楚世峰, 王真真,陈乃宏*.GSK3在抑郁症发病机制中的研究进展. 神经药理学报, 2014; 4: 44-54.

74.   娄钰霞, 张 钊, 王真真,姜懿纳, 张 毅, 李 林, 陈乃宏*.帕金森病相关基因DJ-1与氧化应激. 神经药理学报, 2016; 6(1): 58-64.

75.   李英华, 田晓峰, 王真真,张雪松, 张峰, 金松, 姚继红*. NF-κB对肠缺血再灌注肝损伤P-选择素表达和中性粒细胞浸润的作用. 世界华人消化杂志, 2006; 14: 486-490.

76.   娄钰霞, 李婧, 夏聪媛, 王真真, 陈乃宏*. 糖皮质激素水平升高损伤大鼠前额皮层缝隙连接结构和功能. 药学学报, 2018;53 (10): 1645−1651.

77.   赵楠, 安磊, 张有志, 王真真, 李云峰*. 小鼠获得性无助抑郁模型的优化与评价. 军事医学, 2013; 37: 439-444.

78.   夏晖, 刘艳芹, 薛瑞, 王真真, 赵楠, 张黎明, 杨日芳*, 陈红霞*, 李云峰*. 抗抑郁候选新药YL-0919对慢性应激大鼠行为及海马树突复杂性的影响. 中国药理学与毒理学杂志,2014; 28: 823-829.

专著

1.      Wang ZZ, Kong LL, Chen NH. GinsenosideRg3. Natural Small Molecule Drugsfrom Plants, edited by Du GH. Singapore: Springer NatureSingapore Pte Ltd. and People's Medical Publishing House, 2018, 509-514.

2.      王真真, 孔令雷，陈乃宏. 人参皂苷Rg3. 《天然药物-来自植物的小分子药物》, 杜冠华主编. 北京: 人民卫生出版社, 2018, 211-214.

3.      王真真, 陈乃宏. 抗衰老药物的临床前药理研究及技术指导原则. 《老年药理学与药物治疗学》, 张洪泉主编. 北京: 人民卫生出版社, 2010, 932-946.

4.      王真真, 张有志, 李云峰. 抗精神分裂症的多靶点药物. 《多靶点药物研究及应用》, 李学军主编. 北京: 人民卫生出版社, 2011, 252-266.